Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2016 3
2017 3
2018 4
2019 3
2020 6
2021 4
2022 3
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for xinmin xi
Search for Jingmin Xi instead (1 results)
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition).
Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, Zheng S, Wan D, He J, Wang J, Ba Y, Bai C, Bai L, Bai W, Bi F, Cai K, Cai M, Cai S, Chen G, Chen K, Chen L, Chen P, Chi P, Dai G, Deng Y, Ding K, Fan Q, Fang W, Fang X, Feng F, Fu C, Fu Q, Gu Y, He Y, Jia B, Jiang K, Lai M, Lan P, Li E, Li D, Li J, Li L, Li M, Li S, Li Y, Li Y, Li Z, Liang X, Liang Z, Lin F, Lin G, Liu H, Liu J, Liu T, Liu Y, Pan H, Pan Z, Pei H, Qiu M, Qu X, Ren L, Shen Z, Sheng W, Song C, Song L, Sun J, Sun L, Sun Y, Tang Y, Tao M, Wang C, Wang H, Wang J, Wang S, Wang X, Wang X, Wang Z, Wu A, Wu N, Xia L, Xiao Y, Xing B, Xiong B, Xu J, Xu J, Xu N, Xu R, Xu Z, Yang Y, Yao H, Ye Y, Yu Y, Yu Y, Yue J, Zhang J, Zhang J, Zhang S, Zhang W, Zhang Y, Zhang Z, Zhang Z, Zhao L, Zhao R, Zhou F, Zhou J, Jin J, Gu J, Shen L. Li J, et al. J Hematol Oncol. 2019 Feb 14;12(1):16. doi: 10.1186/s13045-019-0702-0. J Hematol Oncol. 2019. PMID: 30764882 Free PMC article. Review.
Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
Maimaitiaili A, Chen H, Xie P, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Maimaitiaili A, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):8769-8778. doi: 10.1007/s00432-023-04817-9. Epub 2023 May 2. J Cancer Res Clin Oncol. 2023. PMID: 37129606
Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
Yang C, Guo G, Li B, Zheng L, Sun R, Wang X, Deng J, Jia G, Zhou X, Cui L, Guo C, Zhou X, Leung PSC, Gershwin ME, Shang Y, Han Y. Yang C, et al. Hepatol Int. 2023 Feb;17(1):237-248. doi: 10.1007/s12072-022-10431-7. Epub 2022 Oct 30. Hepatol Int. 2023. PMID: 36309918 Free PMC article. Clinical Trial.
An accurate distinguishing high-risk patients' capacity of Xi'an criterion was confirmed in both early and late-stage PBC. ...Xi'an criterion can facilitate early identification of patients requiring new therapeutic approaches....
An accurate distinguishing high-risk patients' capacity of Xi'an criterion was confirmed in both early and late-stage PBC. ...Xi …
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012).
Chen H, Maimaitiaili A, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Chen H, et al. Ther Adv Med Oncol. 2023 Feb 28;15:17588359231156146. doi: 10.1177/17588359231156146. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36891484 Free PMC article.
P53/NRF2 mediates SIRT1's protective effect on diabetic nephropathy.
Ma F, Wu J, Jiang Z, Huang W, Jia Y, Sun W, Wu H. Ma F, et al. Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1272-1281. doi: 10.1016/j.bbamcr.2019.04.006. Epub 2019 Apr 6. Biochim Biophys Acta Mol Cell Res. 2019. PMID: 30959066 Free article.
34 results